What do systematic reviews say?

Dopamine agonist vs levodopa

Summary of findings: dopamine agonists probably leads to higher number of drop outs due to adverse events compared with levodopa (moderate certainty).

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  OR 1.7
  3 studies · 504 participants
  Moderate

Dopamine agonist vs levodopa

Summary of findings: dopamine agonists showed no clear difference in clinical Global Impressions ‐ Improvement of condition (CGI‐I)… compared with levodopa (moderate certainty).

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  RR 1.19 [0.91, 1.56]
  2 studies · 422 participants
  Moderate

Dopamine agonist vs levodopa

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 344 participants
  Low

Dopamine agonist vs levodopa

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 314 participants
  Moderate

Dopamine agonist vs levodopa

Summary of findings: dopamine agonists showed no clear difference in number of patients experiencing adverse events compared with levodopa (moderate certainty).

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  OR 2.87 [0.43, 19]
  3 studies · 461 participants
  Moderate

Dopamine agonist vs levodopa

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 383 participants
  Moderate

Dopamine agonist vs levodopa

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 39 participants
  Low